about
Military service, deployments, and exposures in relation to amyotrophic lateral sclerosis etiology and survivalCYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine.Single nucleotide polymorphisms in nucleotide excision repair genes, cancer treatment, and head and neck cancer survival.Survival analysis in infectious disease research: describing events in timeStatins and breast cancer prognosis: evidence and opportunities.Comparative Effectiveness of Second-Line Targeted Therapies for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World Observational StudiesEarly and late de novo tumors after liver transplantation in adults: the late onset of bladder tumors in men.Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversyThe association between vitamin K antagonist therapy and site-specific cancer incidence estimated by using heart valve replacement as an instrumental variable.Association of Parity and Time since Last Birth with Breast Cancer Prognosis by Intrinsic Subtype.Effectiveness of aromatase inhibitors and tamoxifen in reducing subsequent breast cancer.Missing doses in the life span study of Japanese atomic bomb survivors.Criminal justice outcomes after engagement in outpatient substance abuse treatment.CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study.Management of stage III colon cancer in the elderly: Practice patterns and outcomes in the general population.Substaging of Lymph Node Status in Resected Pancreatic Ductal Adenocarcinoma Has Strong Prognostic Correlations: Proposal for a Revised N Classification for TNM Staging.Effectiveness and safety of post-induction phase bevacizumab treatment for patients with non-small-cell lung cancer: results from the ARIES observational cohort study.Osteonecrosis of the jaw and survival of patients with cancer: a nationwide cohort study in Denmark.Military service, deployments, and exposures in relation to amyotrophic lateral sclerosis survival.Immortal time bias in retrospective analysis: comment on 'Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma'.Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients.Immortal time bias and reverse causality in retrospective analysis: Comment on "effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study".An unjustified benefit: immortal time bias in the analysis of time-dependent events.Immortal time bias in retrospective analysis: is there a survival benefit in patients with glioblastoma who received prolonged treatment of adjuvant valganciclovir?When to Censor?Immortal person-time bias in the association between herpes zoster and survival following autologous stem cell transplantation.
P2860
Q23915088-F2F10239-F91E-4CE9-9597-CA20525F829CQ30400967-E20552B7-51BC-4692-9DB7-D18C8D73986CQ33896930-1684F861-ED5D-469D-A365-C46A5D567E20Q34195439-E30947E1-05D8-496F-BE1A-7E8209CFD438Q34206487-F5D9E5B6-5C44-4D41-A4C5-8C8CAC61DB32Q34672506-1A308751-2480-4E10-B115-B6D9F173454AQ34778656-4A539DE4-BDCD-486C-83EF-6FEC4B478F0BQ35056229-3D9F278A-34BC-4225-939F-82D8F6F07452Q35747189-62BD9973-87D5-46FB-80C3-B0BE3FF66A25Q36505124-CF02855E-72E8-4E0C-BB3B-F7355B774B81Q36530770-FDFA1223-7EC4-476D-8CE2-E34C5C4D5195Q36668993-9AC40D89-400F-4D05-868F-1912CCC090B6Q37625613-947893AD-14B2-4C7C-83DA-0C075609E22EQ38668766-2820A731-EECA-403D-8D35-8D1204B6921EQ40271928-92D2C94D-E948-48A7-ADEB-1488EF92CC3AQ41371326-02FB45BA-9448-45DB-B56F-7DD7F3C85F12Q41624990-70C217FD-EA75-490B-9789-6B218E4F906BQ42373317-E38CA77B-F8E5-454A-ABA3-924DD4092C44Q42706766-80F0A8A0-76BE-4D77-A4A9-0AEBDE63CF60Q43175122-C125A6D6-22AD-4552-8CE2-15581BE0460FQ47099651-A39727B0-C580-4868-B48E-18FC561A9003Q48084449-C31488D2-A41E-4E25-AC16-4608B48939EFQ48200488-59FF0443-1BF5-46CB-A547-5CAC6B88A85CQ48386337-7FFE2065-C0BC-45C9-ABC3-F9DF38321514Q50094102-23DFB0B4-B185-42F9-8C60-F118B0D49182Q51038478-E6811B19-7B0B-4B7C-9810-42B9D34686FE
P2860
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Immortal person-time in studies of cancer outcomes.
@en
Immortal person-time in studies of cancer outcomes.
@nl
type
label
Immortal person-time in studies of cancer outcomes.
@en
Immortal person-time in studies of cancer outcomes.
@nl
prefLabel
Immortal person-time in studies of cancer outcomes.
@en
Immortal person-time in studies of cancer outcomes.
@nl
P356
P1476
Immortal person-time in studies of cancer outcomes.
@en
P2093
Stephen R Cole
Timothy L Lash
P356
10.1200/JCO.2009.24.1877
P407
P577
2009-07-13T00:00:00Z